Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome"
Cancer Immunol Immunother. 2016 Jun;65(6):769-70.
doi: 10.1007/s00262-016-1845-2.
Epub 2016 May 19.
1 Melanoma Unit, Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK.
2 Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, 119-129, 08035, Barcelona, Spain. jmartinliberal@gmail.com.